Semaglutide is a glucagon-like peptide 1 (GLP1) analogue which is a synthetic version of a gut-brain axis hormone initially called incretin, because it increased insulin secretion
Once your plan is set, Klinic's care team will verify insurance coverage for the semaglutide treatment and handle the entire prior authorization process for you, from submission to approvalmaking the process hassle-free
doi: 10.1158/1541-7786.MCR-16-0480 40 MukhaAKahyaULingeAChenOLckSLukiyanchukVet al
GLP-1R, a core member of the GPCR family, is widely present on the surfaces of various cells in the human body.1,2 By specifically binding to the key hormone GLP-1, it regulates blood glucose levels and lipid metabolism.3,4 This receptor and its agonists hold significant therapeutic potential, reshaping the treatment approaches for multiple diseases, including diabetes, cardiovascular disorders, and neurodegenerative diseases .5,6,7 GLP-1 is a peptide produced by the cleavage of proglucagon, mainly synthesized in the intestinal mucosal L-cells, pancreatic islet -cells, and neurons in the nucleus of the solitary tract.3,4 GLP-1RAs mimic the action of endogenous GLP-1, activating GLP-1R, thereby enhancing insulin secretion, inhibiting glucagon release, delaying gastric emptying, and reducing food intake through central appetite suppression.8,9,10 These mechanisms make GLP-1RAs powerful tools for controlling blood glucose and improving metabolic syndrome
